Advanced

Adding formoterol to budesonide in moderate asthma--health economic results from the FACET study

Andersson, F; Stahl, E; Barnes, P J; Löfdahl, Claes-Göran LU ; O'Byrne, P M; Pauwels, R A; Postma, D S; Tattersfield, A E and Ullman, A (2001) In Respiratory Medicine 95(6). p.505-512
Abstract
The FACET (Formoterol and Corticosteroid Establishing Therapy) study established that there is a clear clinical benefit in adding formoterol to budesonide therapy in patients who have persistent symptoms of asthma despite treatment with low to moderate doses of an inhaled corticosteroid. We combined the clinical results from the FACET study with an expert survey on average resource use in connection with mild and severe asthma exacerbations in the U.K., Sweden and Spain. The primary objective of this study was to assess the health economics of adding the inhaled long-acting beta2-agonist formoterol to the inhaled corticosteroid budesonide in the treatment of asthma. The extra costs of adding the inhaled beta2-agonist formoterol to the... (More)
The FACET (Formoterol and Corticosteroid Establishing Therapy) study established that there is a clear clinical benefit in adding formoterol to budesonide therapy in patients who have persistent symptoms of asthma despite treatment with low to moderate doses of an inhaled corticosteroid. We combined the clinical results from the FACET study with an expert survey on average resource use in connection with mild and severe asthma exacerbations in the U.K., Sweden and Spain. The primary objective of this study was to assess the health economics of adding the inhaled long-acting beta2-agonist formoterol to the inhaled corticosteroid budesonide in the treatment of asthma. The extra costs of adding the inhaled beta2-agonist formoterol to the corticosteroid budesonide in asthmatic patients in Sweden were offset by savings from reduced use of resources for exacerbations. For Spain the picture was mixed. Adding formoterol to low dose budesonide generated savings, whereas for moderate doses of budesonide about 75% of the extra formoterol costs could be recouped. In the U.K., other savings offset about half of the extra cost of formoterol. All cost-effectiveness ratios are within accepted cost-effectiveness ranges reported from previous studies. If productivity losses were included, there were net savings in all three countries, ranging from Euro 267-1183 per patient per year. In conclusion, adding the inhaled, long-acting beta2-agonist formoterol to low-moderate doses of the inhaled corticosteroid budesonide generated significant gains in all outcome measures with partial or complete offset of costs. Adding formoterol to budesonide can thus be considered to be cost-effective. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
formoterol, asthma, FACET, cost-effectiveness, long-acting β2-agonist, budesonide.
in
Respiratory Medicine
volume
95
issue
6
pages
505 - 512
publisher
Elsevier
external identifiers
  • pmid:11421509
  • scopus:0034935405
ISSN
1532-3064
DOI
10.1053/rmed.2001.1078
language
English
LU publication?
yes
id
cc27dbca-5a8f-43e3-b03b-afb5174da42a (old id 1122241)
date added to LUP
2008-06-23 15:56:52
date last changed
2018-01-07 09:05:44
@article{cc27dbca-5a8f-43e3-b03b-afb5174da42a,
  abstract     = {The FACET (Formoterol and Corticosteroid Establishing Therapy) study established that there is a clear clinical benefit in adding formoterol to budesonide therapy in patients who have persistent symptoms of asthma despite treatment with low to moderate doses of an inhaled corticosteroid. We combined the clinical results from the FACET study with an expert survey on average resource use in connection with mild and severe asthma exacerbations in the U.K., Sweden and Spain. The primary objective of this study was to assess the health economics of adding the inhaled long-acting beta2-agonist formoterol to the inhaled corticosteroid budesonide in the treatment of asthma. The extra costs of adding the inhaled beta2-agonist formoterol to the corticosteroid budesonide in asthmatic patients in Sweden were offset by savings from reduced use of resources for exacerbations. For Spain the picture was mixed. Adding formoterol to low dose budesonide generated savings, whereas for moderate doses of budesonide about 75% of the extra formoterol costs could be recouped. In the U.K., other savings offset about half of the extra cost of formoterol. All cost-effectiveness ratios are within accepted cost-effectiveness ranges reported from previous studies. If productivity losses were included, there were net savings in all three countries, ranging from Euro 267-1183 per patient per year. In conclusion, adding the inhaled, long-acting beta2-agonist formoterol to low-moderate doses of the inhaled corticosteroid budesonide generated significant gains in all outcome measures with partial or complete offset of costs. Adding formoterol to budesonide can thus be considered to be cost-effective.},
  author       = {Andersson, F and Stahl, E and Barnes, P J and Löfdahl, Claes-Göran and O'Byrne, P M and Pauwels, R A and Postma, D S and Tattersfield, A E and Ullman, A},
  issn         = {1532-3064},
  keyword      = {formoterol,asthma,FACET,cost-effectiveness,long-acting β2-agonist,budesonide.},
  language     = {eng},
  number       = {6},
  pages        = {505--512},
  publisher    = {Elsevier},
  series       = {Respiratory Medicine},
  title        = {Adding formoterol to budesonide in moderate asthma--health economic results from the FACET study},
  url          = {http://dx.doi.org/10.1053/rmed.2001.1078},
  volume       = {95},
  year         = {2001},
}